PAVmed Inc (PAVM) Jumps 16.5%

On an overall negative day for the PRISM Stock Indexes, PAVmed stood out with a very positive day. PAVM jumped 16.5%, ending with a share price of $1.27 and a daily high of around $1.40.

PAVM is located in the MedDevices and MedDiagnostics indexes, which finished -1.2% and -0.2%, respectively.

PAVM announced yesterday, that the Company will hold a Business Update Conference Call on May 12, 2022.

About PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology, and glucose monitoring. For more information, please visit

Share This Article


About the Author

PAVmed Inc (PAVM) Jumps 16.5%

Editor Prism MarketView